Bench to Bedside: Chemistry of Health Care

Drug Conjugates: Approaches to Delivering Active Drugs to Where they are Needed (#385)

Advancements in the understanding of the biochemical basis of diseases coupled with new techniques in drug design have enhanced our ability to devise chemical agents that are effective modulators of disease processes. However, in many cases, biochemically active molecules are not good drugs due to problems related to factors other than their ability to interact with a particular biological target. Problems with bioavailability, stability, pharmacokinetics, tissue distribution, or access to the intended molecular target may prevent the development of otherwise promising new drugs. Chemistry-based drug delivery technologies have shown great promise in overcoming many of these issues. Conjugation of small molecule drugs or other biologically-active agents to antibodies or other targeting molecules can help to deliver active agents selectively to specific tissue or cell types. Attachment of cell penetration enhancers can help drugs cross biological barriers to reach intracellular targets. Incorporation of drugs in macromolecules or nanoparticles can modify a drug’s distribution or its half-life. In this symposium, the use of chemical or biochemical conjugation to address issues of drug delivery will be explored. Recent advances in the discovery and development of antibody-drug conjugates, polymer- and macromolecular-based conjugates, tissue-specific pro-drug activation and other chemistry-based drug-delivery technologies will be discussed. Invited and contributed presentations will cover the basic science and pharmaceutical development of conjugated drugs.

Confirmed speakers include: Paul Wender (Stanford U), Peter Senter (Seattle Genetics), Robert Young (Simon Fraser U), Thomas Pillow (Genentech), Hongang Cui (Johns Hopkins)
Last update: Dec 28, 2015